Form 4: Hims & Hers Health Chief Legal Officer Sells Shares Under 10b5-1 Plan

Sentiment:

SEC Form 4


Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., executed stock option exercises and sales of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

  • On March 13, 2024, Soleil Boughton, the Chief Legal Officer of Hims & Hers Health, Inc., exercised stock options to acquire 63,621 shares of Class A Common Stock at a price of $2.43 per share.
  • Simultaneously, Boughton sold 63,621 shares of Class A Common Stock at an average weighted price of $15.1682, with prices ranging from $15.00 to $15.375.
  • These transactions were conducted under a Rule 10b5-1 trading plan adopted on September 8, 2023.
  • Following these transactions, Boughton directly owns 154,345 shares of Class A Common Stock and 113,769 stock options.
  • The stock options vest monthly over a four-year period from February 12, 2020, and are now fully vested.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions were part of a pre-planned trading plan and do not necessarily indicate a change in the executive's confidence in the company.

Positives

  • The transactions were conducted under a pre-arranged 10b5-1 trading plan, which is generally viewed as a positive corporate governance practice.

Risks

  • Executive stock sales can sometimes be perceived negatively by investors, although the use of a 10b5-1 plan mitigates this concern.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

  • The vesting schedule of the options (four years with monthly vesting) is a fairly standard practice in the tech and healthcare industries.
  • The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the telehealth sector like Teladoc and Amwell, to manage their stock sales in a compliant manner.

Stakeholder Impact

  • The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan should mitigate concerns about insider trading.

Key Dates

DateDescription
February 12, 2020Start date for monthly vesting of stock options.
September 8, 2023Date of adoption of the Rule 10b5-1 trading plan.
March 13, 2024Date of stock option exercise and sale of shares.
March 15, 2024Date of signature on the Form 4 filing.
May 12, 2030Expiration date of the stock options.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.